Key facts
- This page summarizes Semigran Marc's Form 4 filing for Edgewise Therapeutics, Inc. (EWTX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 14 Aug 2024, 16:15.
Semigran Marc - 12 Aug 2024 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)
- Reporting relationship
- Chief Development Officer
- Issuer ticker
- EWTX
- Reported as of
- 12 Aug 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Aug 2024, 16:15:40 UTC
- Prior SEC filing
- 18 Aug 2023
- Next SEC filing
- 27 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ John R. Moore, Attorney-in-Fact for Semigran Marc
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Semigran Marc filed Form 4 for Edgewise Therapeutics, Inc. (EWTX) on 14 Aug 2024.
Change
- Previous filing in this sequence was filed on 18 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EWTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +138,750
- Change %
- Price
- $0.000000
- Shares after
- 138,750
- Date
- 12 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 138,750
- Exercise price
- $17.05
- Footnotes
- F1
EWTX
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +23,125
- Change %
- Price
- $0.000000
- Shares after
- 23,125
- Date
- 12 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 23,125
- Exercise price
- $0.000000
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
1/48th of the shares subject to the option vest each month beginning on August 12, 2024, subject to the Reporting Person continuing as a service provider through each vest date.
Footnote F2
Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2024.